NMTR Insider Trading

Insider Ownership Percentage: 2.40%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

9 Meters Biopharma Insider Trading History Chart

This chart shows the insider buying and selling history at 9 Meters Biopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50k$0$50kTotal Insider BuyingTotal Insider Selling

9 Meters Biopharma Share Price & Price History

Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 04/8/2025 01:00 AM ET

This chart shows the closing price history over time for NMTR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JanFebMarAprMayJunJulAugSepOctNovDec$0.07Closing price on 12/16/24:

9 Meters Biopharma Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for 9 Meters Biopharma (NASDAQ:NMTR)

22.34% of 9 Meters Biopharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at NMTR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1$0Total InflowsTotal Outflows
9 Meters Biopharma logo
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.
Read More on 9 Meters Biopharma

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

315,915 shs

Market Capitalization

$1.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.36

Who are the company insiders with the largest holdings of 9 Meters Biopharma?

9 Meters Biopharma's top insider shareholders include:
  1. Bethany Sensenig (CFO)
Learn More about top insider investors at 9 Meters Biopharma.